Results 31 to 40 of about 267,464 (292)

Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]

PLoS Computational Biology, 2013
T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis, Matt Maybeno, Jason A Greenbaum, Daniela Weiskopf, Aruna D De Silva, Alessandro Sette, Can Keşmir, Bjoern Peters   +7 more
doaj   +1 more source

Baseline characteristics of immunogenicity cohort.

, 2021
Baseline characteristics of immunogenicity cohort.
Ousmane Guindo (35279), Monica Malone McNeal (11067898), Souna Garba (11067904), Céline Langendorf (624676), Eric Adehossi (308400), Iza Ciglenecki (446458), Brian Plikaytis (11067901), Rebecca F. Grais (8151654), Sheila Isanaka (323429)   +8 more
core   +1 more source

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity [PDF]

, 2012
© 2012 Elsevier Ltd. All rights reservedBackground: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority.
Sander, C, Angela M Minassian, Nicola Williams, Lawrie, AM, Alison M Lawrie, Rowland, R, Poulton, ID, Rosalind Rowland, Brittain, N, Pathan, AA, David W Porter, Minassian, AM, Helen McShane, Iman Satti, Ansar A Pathan, Ian D Poulton, Nathaniel Brittain, Williams, N, Clare Sander, Porter, DW, Satti, I, McShane, H   +21 more
core   +1 more source

Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo [PDF]

, 2004
Strategies to enhance the immunogenicity of tumors are urgently needed. Although vaccination with irradiated dying lymphoma cells recruits a tumor-specific immune response, its efficiency as immunogen is poor.
Zimmermann, VS, Voll, Reinhard E., Turnay, Javier, Manfredi, Angelo A., Turnay, J, Dumitriu, IE, Voll, RE, Zimmermann, Valérie S, Angelo A. Manfredi, Bertling, Wolf, Rovere-Querini, P, Kalden, JR, Udo S. Gaipl, Herrmann, M, Attilio Bondanza, Gaipl, Udo S, Wolf Bertling, Bertling, W, Patrizia Rovere-Querini, Ingrid E. Dumitriu, Bondanza, Attilio, Stach, Christian M., Pöschl, E, Stach, Christian M, Gaipl, US, Javier Turnay, Herrmann, Martin, Martin Herrmann, Dumitriu, Ingrid E., Rovere-Querini, Patrizia, Christian M. Stach, Manfredi, Angelo A, Kalden, Joachim R, Valérie S. Zimmermann, Pöschl, Ernst, Stach, CM, Dumitriu, Ingrid E; id_orcid, Gaipl, Udo S., Joachim R. Kalden, Bondanza, A, Zimmermann, Valérie S., Voll, Reinhard E, Kalden, Joachim R., Reinhard E. Voll, Manfredi, AA, Ernst Pöschl, Dumitriu IE, Kalden JR, Bertling W, Turnay J, Herrmann M., Poschl E, Zimmermann VS, Gaipl US, Stach CM, Voll RE, BONDANZA , ATTILIO, ROVERE QUERINI , PATRIZIA, MANFREDI , ANGELO ANDREA M. A.   +58 more
core   +1 more source

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

Frontiers in Oncology, 2023
In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients.
Yuki Katsuya, Yuki Katsuya, Shigehisa Kitano, Makiko Yamashita, Mayu Ouchi, Shigehiro Yagishita, Akinobu Hamada, Akinobu Hamada, Hiromi Nakamura, Fumie Hosoda, Tatsuhiro Shibata, Noriko Motoi, Noriko Motoi, Takayuki Nakayama, Takashi Seto, Shigeki Umemura, Yukio Hosomi, Miyako Satouchi, Makoto Nishio, Toshiyuki Kozuki, Toyoaki Hida, Toyoaki Hida, Yuichiro Ohe, Hidehito Horinouchi   +23 more
doaj   +1 more source

Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. [PDF]

, 2022
In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity.
Michael Kammüller, Isabelle Beley, Cordier, Valerie, Schindler, Patrick, Patoux, Agnes, Agnes Patoux, Brees, Dominique, Mateusz Piksa, Valerie Cordier, Stöllner, Daniela, Babette Wolf, von Gunten, Stephan, Bernd Voedisch, Dominique Brees, Patrick Schindler, Besson, Thierry, Daniela Stöllner, Kammueller, Michael, Ludovic Perrot, Stephan von Gunten, Beley, Isabelle, Kammüller, Michael, Wolf, Babette, Thierry Besson, Voedisch, Bernd, Perrot, Ludovic, Piksa, Mateusz   +26 more
core   +2 more sources

Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

Frontiers in Bioengineering and Biotechnology, 2023
CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA.
Radwa Ewaisha, Radwa Ewaisha, Karen S. Anderson   +2 more
doaj   +1 more source

Applying MAPPs assays to assess immunogenicity

, 2020
Immunogenicity against biotherapeutic proteins (BPs) and the outcome for the patient are difficult to predict. In vitro assays that can help to assess the immunogenic potential of BPs are not yet used routinely during drug development.
Karle, Anette
core   +1 more source

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

Journal of Immunology Research, 2016
Today, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity.
Anshu Kuriakose, Narendra Chirmule, Pradip Nair   +2 more
doaj   +1 more source

Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis

, 2017
Although anti-drug antibodies against biologics have been associated with decreased clinical efficacy, the immunogenicity of biologics seems to vary between drugs, diseases and ethnicities.
蔡呈芳;詹智傑;邱顯鎰;林頌然, Chiu, Hsien-Yi;Wang, Ting-Shun;Chan, Chih-Chieh;Lin, Sung-Jan;Tsai, Tsen-Fang   +1 more
core   +1 more source